Navigation Links
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:10/31/2008

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed

Following a Rituximab-Containing Regimen

FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The data supporting the FDA approval show that TREANDA is effective, has a tolerable side effect profile in patients with indolent NHL and that treatment results in a high durable response rate. In March of this year, TREANDA received approval for the treatment of patients with chronic lymphocytic leukemia, the most common form of leukemia in the United States.

Indolent NHL, a subset of non-Hodgkin's lymphoma, is a slow growing but serious cancer of the lymphatic system that is not curable with currently available treatments. Patients with indolent NHL are prone to multiple relapses after initial therapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed this year with indolent NHL.

"Because most patients with indolent non-Hodgkin's lymphoma eventually become resistant to existing treatments, new treatment options like TREANDA are needed to improve patient outcome," stated Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C. and TREANDA clinical investigator. "The TREANDA pivotal trial shows that it is an effective and well-tolerated chemotherapy that offers a delay in disease progression for more than nine months."

According to Dr. Lesley Russell, Executive Vice President and Chief Medical Officer, Cephalon, "We are excited about this seco
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
2. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
3. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
4. Cephalon Conference Call Invitation
5. Cephalon Reports Strong First Quarter Earnings
6. Cephalon Appoints Gerald J. Pappert as General Counsel
7. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
8. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
9. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... intact cells to treat and cure disease is ... is hindered by the inability of doctors and scientists ... these cells in patients without resorting to invasive procedures, ... 17 in the online journal Magnetic Resonance in ... Diego School of Medicine, University of Pittsburgh and elsewhere ...
Breaking Medicine News(10 mins):Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2
... Ann Converso, RN, to Serve as President, WASHINGTON, ... the death of President Cheryl L. Johnson,RN. Johnson was ... Oct. 19, with a ruptured brain aneurysm and died ... friends., "Cheryl was a guiding force in the ...
... BASEL, Switzerland, Oct. 29 Roche (SWX: ROG.VX; RO.S),a ... it has extended its offer to acquire all of ... VMSI ),to 5:00 p.m., New York City time ... scheduled to expire at 5:00 p.m., New York City ...
... experts will summarize important new research on the ... consequences of acute kidney injury, racial and ethnic ... kidney disease patients, being presented during the American ... Exposition in San Francisco at a policy-centered news ...
... Fund Launch National Campaign to Inspire and ... Educate that Prevention is Possible, BERKELEY, Calif., Oct. ... in their lifetime. Although 50 percent,of women think breast cancer is ... of the disease. LUNA, the makers of whole nutrition bars ...
... ... Provider Earns $1.6 Million in Rebates This Year, Highlights ... Redwood City Project, REDWOOD ... nation,s largest not-for-profit,health plan, will today celebrate significant energy efficiency upgrades,and solar installations ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... announced today that it will present at the,18th ... York City. The,Company,s presentation is scheduled for Monday, ... Hinson, president and chief executive officer, will,review the ...
Cached Medicine News:Health News:UAN Mourns Passing of President Cheryl L. Johnson, RN 2Health News:Roche Extends Tender Offer for Ventana 2Health News:Roche Extends Tender Offer for Ventana 3Health News:Roche Extends Tender Offer for Ventana 4Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:The Healing Power of Green 2Health News:The Healing Power of Green 3Health News:Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 2
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/19/2014)... September 19, 2014 Reductions in ... many years in people with diabetes type 2 ... term benefits for the kidneys." Australian researchers ... type 2 diabetes leads to persistent reductions in kidney ... The global study has found that, five and ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... July 20, 2011 One of Frantz Medical Group,s ... it has been awarded an Ohio Third Frontier grant ... system for penetrating through vascular Chronic Total Occlusions (CTOs), ... Coronary Artery Bypass Graft (CABG).   VasoStar,s ...
... VEGAS, July 20, 2011 Cardinal Health today announced ... national trade show for independent pharmacies, is the largest ... attendees. This year,s event, taking place ... Palazzo resort hotel, features a 100,000-square-foot trade show floor, ...
Cached Medicine Technology:Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 2Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 3Nearly 7,000 Participate in Cardinal Health's Largest-Ever Annual Trade Show for Independent Pharmacies 2Nearly 7,000 Participate in Cardinal Health's Largest-Ever Annual Trade Show for Independent Pharmacies 3Nearly 7,000 Participate in Cardinal Health's Largest-Ever Annual Trade Show for Independent Pharmacies 4
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Delicate strong curved serrated tips. Serrated handle with dull finish....
Medicine Products: